Tempus
The multinational pharma company will access Tempus' AI-enabled data library to further therapeutic development and advance its portfolio in oncology.
The multinational pharma company will now be able to access Tempus' de-identified patient data.
Also: Digital education videos could improve patient consent; Tempus launches new app for physicians.